International Journal of Pharmacology1811-77751812-5700Asian Network for Scientific Information10.3923/ijp.2018.1145.1152LuHuizhi TanYun YangLuyu DongHui LiaoYouxia CaoSong FuShouzhi 82018148Background and Objective: Heart failure or myocardial infarction (MI) is one of the deadliest condition which claims many lives globally. This pre-clinical animal study was intended to investigate the beneficial role of Tangeretin (TAN) against isoproterenol (ISO) induced heart failure in a rat model. Materials and Methods: Forty healthy male rats were randomly separated into four group with 10 rats in each. Saline treat rats are considered as a control group, whereas ISO (85 mg kg1, i.p) induced rats (2 consecutive days) are considered as ISO group. The TAN (100 mg kg1 via o.p) pretreated rats for 28 days followed by induction of ISO will be considered as SAB-B+ISO group, only TAN (100 mg kg1, o.p) received rats for 28 days are considered as TAN group. Results: A pronounced increase in the levels of various hemodynamic parameters and the activities of antioxidants were observed in TAN pre-treated rats as compared to ISO-induced rats. However, the levels of infarct size, lipid peroxidation product like MDA, inflammatory markers, apoptotic markers are significantly decreased upon treatment with TAN for 28 days. Furthermore, TAN administration markedly reverted the histomorphological changes (cardiac tissue) caused by ISO induction. Conclusion: Taking together, that 28 days of pre-treatment with TAN significantly preserved cardiac function by suppressing oxidative stress, inflammation, apoptosis in ISO-induced heart failure (myocardial infarction) model and hence it can be recommended to treat myocardial infarction/heart failure with conventional (standard) cardio protective agents.]]>WHO.,2011Pages: 162Pages: 162Xu, H., W. Li, J. Yang, S.D. Wiviott and M.S. Sabatine et al.,2016175193201Kumar, M., E.R. Kasala, L.N. Bodduluru, V. Dahiya and M. Lahkar,201665613622Zhou, R., Q. Xu, P. Zheng, L. Yan, J. Zheng and G. Dai,2008586244250Sharma, M., K. Kishore, S.K. Gupta, S. Joshi and D.S. Arya,2001Ocimum sanctum in isoproterenol induced myocardial infarction in rats.]]>2257583Sagor, M., A. Taher, N. Tabassum, M. Potol and M. Alam,20152015Prabha, S.P., A. Nitha, P.N. Ansil and M.S. Latha,2014Gardenia gummifera Linn. F. on isoproterenol induced myocardial infarction in rats.]]>538173828Deng, X.Y., J.J. Chen, H.Y. Li, Z.Q. Ma, S.P. Ma and Q. Fu,2015Anemarrhenae asphodeloides Bge on isoproterenol-induced myocardial infarction in rats.]]>2402228Sundaram, R., P. Shanthi and P. Sachdanandam,201516315333Sundaram, R., P. Shanthi and P. Sachdanandam,201421793799Periyasamy, K., K. Baskaran, A. Ilakkia, K. Vanitha, S. Selvaraj and D. Sakthisekaran,201575263272Shu, Z., B. Yang, H. Zhao, B. Xu and W. Jiao et al.,201419275282Walle, T. and U.K. Walle,200759857862Pan, M.H., W.J. Chen, S.Y. Lin-Shiau, C.T. Ho and J.K. Lin,20021 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells.]]>2316771684Li, R.W., A.G. Theriault, K. Au, T.D. Douglas, A. Casaschi, E.M. Kurowska and R. Mukherjee,200679365373Green, C.O., A.O. Wheatley, D.A. Mcgrowder, L.L. Dilworth and H.N. Asemota,201351306309Wang, Y., X. Li, X. Wang, W. Lau and Y. Wang et al.,20132013Xu, L., Y. Deng, L. Feng, D. Li and X. Chen et al.,20112011Goyal, S.N., S. Arora, A.K. Sharma, S. Joshi and R. Ray et al.,2010Crocus sativus on hemodynamic, biochemical, histopathological and ultrastuctural alterations in isoproterenol-induced cardiotoxicity in rats.]]>17227232Liang, F., Y. Fang, W. Cao, Z. Zhang, S. Pan and X. Xu,2018tert-Butyl Hydroperoxide (t-BHP)-induced oxidative damage in HepG2 cells by Tangeretin: Relevance of the Nrf2-ARE and MAPK signaling pathways.]]>6663176325Omar, H.A., W.R. Mohamed, H.H. Arab and E.S.A. Arafa,20162016